Subcutaneous Immunoglobulin (SCIg) Treatment
SCIg is self-administered at home by the patient, whereas IVIg requires an outpatient clinic or hospital setting. Switching from IVIg to SCIg reconfigures the patient's role in treatment administration, alters the impact on daily life, and…
1 sources - 4 claims
SCIg is self-administered at home by the patient, whereas IVIg requires an outpatient clinic or hospital setting. Switching from IVIg to SCIg reconfigures the patient's role in treatment administration, alters the impact on daily life, and changes healthcare contact patterns. Changes in immunoglobulin variant, medical equipment, or dosage can temporarily destabilise established patient routines. Post-treatment physical discomfort including fluid accumulation under the skin and seepage from needle sites can limit physical activity after high-dose sessions.